Aurinia Pharmaceuticals | 8-K: Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS ® Growth and AUR200 Development
Aurinia Pharmaceuticals | 8-K: Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS ® Growth and AUR200 Development
Aurinia Pharmaceuticals | 8-K:Aurinia Pharmicals 公布了 2024 年第三季度和九个月的财务和经营业绩,宣布进行战略重组,以进一步关注 LUPKYNIS® 的持续增长和 AUR200 的发展